LENZ Therapeutics Inc [LENZ] stock is trading at $31.94, up 8.05%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LENZ shares have gain 24.28% over the last week, with a monthly amount drifted -0.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on March 18, 2025, and set its price target to $60. On September 27, 2024, Raymond James initiated with an Outperform rating and assigned a price target of $37 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $38 on August 12, 2024. William Blair initiated its recommendation with an Outperform. Leerink Partners started tracking with an Outperform rating for this stock on April 15, 2024, and assigned it a price target of $32. In a note dated April 10, 2024, Citigroup initiated a Buy rating and provided a target price of $34 on this stock.
LENZ Therapeutics Inc [LENZ] stock has fluctuated between $16.53 and $50.40 over the past year. Currently, Wall Street analysts expect the stock to reach $61.5 within the next 12 months. LENZ Therapeutics Inc [NASDAQ: LENZ] shares were valued at $31.94 at the most recent close of the market. An investor can expect a potential return of 92.55% based on the average LENZ price forecast.
Analyzing the LENZ fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -12.23%, Pretax Profit Margin comes in at -10.24%, and Net Profit Margin reading is -10.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.26 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.87 points at the first support level, and at 27.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.07, and for the 2nd resistance point, it is at 34.20.
Ratios To Look Out For
For context, LENZ Therapeutics Inc’s Current Ratio is 12.69. Also, the Quick Ratio is 12.63, while the Cash Ratio stands at 3.62. Considering the valuation of this stock, the price to sales ratio is 57.11, the price to book ratio is 4.71.
Transactions by insiders
Recent insider trading involved Olsson Shawn, Chief Commercial Officer, that happened on Nov 17 ’25 when 10000.0 shares were sold. Officer, SHAWN OLSSON completed a deal on Nov 17 ’25 to buy 40000.0 shares. Meanwhile, Director MCCOLLUM JAMES W bought 10500.0 shares on Nov 07 ’25.
